6008集团

LF01获批临床，是活体生物药物医治恶性肿瘤的一次新的突破，充分印证了南芯医疗在微生态领域确当先职位，及其长达8年的深厚积淀和怪异优势，也为6008集团临床前研发服务平台增新添成功案例！

HB0052在美国获批临床，不仅开启华奥泰全球化战术的关键一步，硬核展示了华奥泰深厚的自主研发和技术创新实力，以及美满的抗体偶联药物研发平台，也是6008集团抗体药物偶联物（ADC）研发服务平台急剧落地的又一个成功案例。

这次GT929新药实现中美双报双批，再次验证和体现了标新生物GLUETACS?平台急剧发现候选药物和管线推动的能力，也是标新生物全球化过程的又一里程碑。

这次LX-132获批临床，显示了力鑫生物在幼分子共价抑造剂创新药研发领域的创新能力，也再次验证了6008集团一站式生物医药临床前研发服务平台的赋能实力。

Replication stress (RS) is a cancer hallmark; chemotherapeutic drugs targeting RS are widely used as treatments for various cancers. To develop next-generation RS-inducing anticancer drugs, cell division cycle 7 (CDC7) has attracted attention as a target. Researchers have developed an oral CDC7-selective inhibitor, TAK-931, as a candidate clinical anticancer drug. TAK-931 demonstrated marked, dose-dependent antitumor activity, without severe body weight loss. Antitumor efficacy studies for TAK-931 were carried out in two pancreatic PDX models, PHTX-249Pa and PHTXM-97Pa, at Medicilon.

这次ABM-1310获美国FDA孤儿药资格认证，不仅显露了璧辰医药全球化创新的不凡实力，也阐发了其在幼分子入脑药物领域的领军职位。

YY201获得临床获批不仅代表了宇耀生物又一重要突破，验证了宇耀生物超等分子胶技术平台和AI药物辅助开发平台的创新能力，同时也证了然6008集团临床前钻研的技术服务力量。

6008集团为NB002提供了安全性评价、药代动力学等临床前钻研服务，助力其IND申请顺利获FDA临床许可。

6008集团为BIOT-001的研发提供了从靶点到IND申报的临床前研发服务，全力促成该项目高质高效实现。

?Alzheimer's disease (AD) is the most universal age-related neurodegenerative disease. AP39 is a newly synthesized mitochondrially targeted H2S donor on mitochondrial function. AP39 increases intracellular H2S levels, mainly in mitochondrial regions. AP39 exerts dose-dependent effects on mitochondrial activity in APP/PS1 neurons. AP39, a novel mitochondria-targeted H2S donor, was designed and synthesized by Medicilon.